PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

Summary

This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit \>48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4 weeks to maintain hematocrit \<45% with a target of \<43%. Subjects may receive PTG-300 treatment for up to 52 weeks.

Timeline

Start

2021-02-02

Primary completion

2023-03-15

Completion

2023-03-15

Drugs

Indications